Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466752 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
A Phase 2 study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00466752 is a Phase 2 study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer that has completed, run by University of Washington. The registered enrollment target is 5 participants, below the 109-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00466752, a Phase 2 study of Adenocarcinoma of the Prostate and Stage III Prostate Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Studying samples of blood and tumor tissues in the laboratory from patients with prostate cancer may help doctors learn more about changes that occur in DNA after treatment with sorafenib tosylate
Conditions Studied
Interventions
- GENETIC gene expression analysis
- GENETIC microarray analysis
- OTHER immunohistochemistry staining method
- DRUG sorafenib tosylate
- PROCEDURE needle biopsy
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00466752
The ClinicalTrials.gov registry entry for NCT00466752 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (95% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00466752 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00466752 about?
NCT00466752 is a clinical study titled "Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer". This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Studyin...
What is the current status of trial NCT00466752?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-12. Estimated completion is 2011-07-01.
What conditions does trial NCT00466752 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage II Prostate Cancer.
What interventions are being tested in trial NCT00466752?
The interventions under investigation include: gene expression analysis (GENETIC), microarray analysis (GENETIC), immunohistochemistry staining method (OTHER), sorafenib tosylate (DRUG), needle biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT00466752?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00466752 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
COMPLETED · Phase 2
-
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
COMPLETED · Phase 2
-
Enzalutamide in Patients With High-risk Prostate Cancer
COMPLETED · Phase 2
-
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
COMPLETED · Phase 2
-
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.